After what has been deemed a 鈥渇unding winter鈥� for life science SMEs, building a strong data package to attract larger capital in the current climate is as important as ever, says Jordy Breuker, associate capital advisory at the financial services provider F.Institute.
Breuker was speaking on a panel discussing the macro-environmental factors impacting life sciences R&D companies at the BioTrinity conference, which took place 23-24 April, in London, UK.
In 2023, biotech funding dropped by 43.2% compared to 2022 and by 52.3% from 2021, due to macroeconomic pressures like high inflation, high interest rates, and geopolitical instability. This made investors more cautious and pushed them to prioritise existing portfolios.
鈥淚t’s well known that it’s been a tough year. Looks like we’re heading out, but there’s definitely still a problem. What we see is there’s a backlog of a couple of years, companies waiting to be financed both the very early stage and the later stage,鈥� said Breuker.
Breuker emphasised that life science SMEs should focus on ensuring R&D is as strong as it can be to attract investors: 鈥淩eally strengthen the knowledge base from MOA [mechanism of action] to assays [so] you can really understand the molecule.
鈥淭his also means that you can be a bit more bold in your financing strategy. So instead of trying to shave off some money here and there, try and think big, really build out your R&D and funding roadmap to build the strongest data package that you can. I think that’s a clear trend to move out of this funding winter,鈥� says Breuker.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOxford University Innovation鈥檚 CEO Steve Silvey explained that while there is enough capital available, it鈥檚 not being invested quickly because the opportunities to invest in good deals are limited, and the values are lower for the capital.
鈥淚nnovative companies are thinking bigger, and [asking] how can we offer a very compelling proposition to the right investor that allows us to attract capital鈥� to effectively see us through this time and build a more compelling and bigger vision for our business as well,鈥� Silvey concludes.
A report on GlobalData鈥檚 Pharma Intelligence Center highlighted that Q1 2024 investment activity witnessed a significant rise in value compared to both the previous quarter and the same period last year, increasing from $5.3bn in Q1 2023 to $7.7 in Q1 2024.
GlobalData is the parent company of 天美传媒app Technology.
